LENSAR, Inc.
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device company that develops and markets laser systems for cataract treatment and management of corneal astigmatism. Its products are the LENSAR Laser System (LLS) and the ALLY Robotic Cataract Laser System, which use imaging, treatment planning and laser… From the company’s description.
Over the twelve months to Jun 30, 2026, LENSAR, Inc. reported revenue of $60.26M, up 3.3% from a year earlier, and net income of $34.70M. Its operating margin was −13.5%, and operations used $7.29M in cash. In fiscal 2025, it reported revenue of $58.44M, up 9.2% from fiscal 2024, and a net loss of $34.28M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What LENSAR, Inc. does
In the company’s own words
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device company that develops and markets laser systems for cataract treatment and management of corneal astigmatism. Its products are the LENSAR Laser System (LLS) and the ALLY Robotic Cataract Laser System, which use imaging, treatment planning and laser technology to assist surgeons with cataract procedures, including incisions, capsulorhexis and lens fragmentation. The systems are sold or leased to ambulatory surgery centers, hospitals and physicians, with associated procedure licenses and consumables also contributing to the business. LENSAR sells directly in the United States and uses third-party distributors in Europe, Asia and other international markets. Its technology includes IntelliAxis Refractive Capsulorhexis, which supports alignment of toric intraocular lenses. The ALLY System combines laser functions in a compact unit designed for use in an operating room or in-office surgical suite. As of December 31, 2025, approximately 435 systems were installed across 17 countries, with about 51% in the United States.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- ORLANDO, FL
- Fiscal year end
- December
- CIK
- 1320350
- SIC
- 3841
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns LENSAR, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · LENSAR, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do LENSAR, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of LENSAR, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in LENSAR, Inc.'s last four quarterly filings that the numbers alone won't show?”